World Parkinson's Day:
Empowering Global Awareness & Research

Since 1997, the European Parkinson's Disease Association (EPDA) has designated April 11th as World Parkinson's Disease Day to commemorate the birthdate of Dr. James Parkinson, the British surgeon who first identified the condition. This international day serves to heighten global awareness about the chronic neurodegenerative disorder and drive profound advancements in related research.

Parkinson's Disease (PD), widely recognized by its hallmark motor symptoms such as resting tremors, rigidity, bradykinesia, and postural instability, is a prevalent neurodegenerative disease affecting a significant portion of the elderly population worldwide. Currently, over 10 million individuals globally live with Parkinson's, and with the accelerating pace of global aging, the prevalence is projected to double to 20 million by 2050, significantly impacting patients' quality of life and placing a heavy burden on healthcare systems. (Want to learn more about Parkinson's Disease? Click here.)

The core pathological features of Parkinson's include the loss of dopaminergic neurons in the substantia nigra and the formation of Lewy bodies, which are primarily composed of aggregated misfolded alpha-synuclein proteins. Although the exact cause remains unclear, potential contributing factors include genetic predisposition, exposure to environmental toxins, oxidative stress, mitochondrial dysfunction, and inflammation. Recent research has gradually unveiled the complex and multifaceted pathophysiology of Parkinson's, encompassing areas such as neuroprotection, neuroregeneration, and immune modulation.

To date, there exists no cure for Parkinson's, with anti-Parkinson's drug development predominantly focusing on symptomatic treatments. While substantial progress has been made in basic research and clinical management of Parkinson's, deeper understanding of its root causes is still required to develop novel drugs that can halt or reverse disease progression. As fundamental medical research advances, treatment strategies for Parkinson's have shifted from conventional dopamine replacement therapies towards exploring deeper disease mechanisms and targeted therapies.

CUSABIO consistently dedicates itself to providing high-quality research reagents such as proteins, antibodies, and ELISA kits to researchers. Given the criticality and urgency of Parkinson's disease research, we have specially curated a list of more than 20 popular targets and related reagent products pertinent to Parkinson's disease studies below for your selection.